Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Operating expenses:
Research and development	$ 27,202	$ 16,965	$ 70,110	$ 46,228
General and administrative	7,840	7,168	26,342	24,861
Total operating expenses	35,042	24,133	96,452	71,089
Loss from operations	(35,042)	(24,133)	(96,452)	(71,089)
Grant income		2,959	157	3,934
Other income, net	2,072	985	5,908	1,651
Net loss	(32,970)	(20,189)	(90,387)	(65,504)
Unrealized gain (loss) on available-for-sale securities	261	(547)	1,278	(2,084)
Comprehensive loss attributable to common stockholders	$ (32,709)	$ (20,736)	$ (89,109)	$ (67,588)
Net loss per share attributable to common stockholders, basic	$ (0.87)	$ (0.53)	$ (2.38)	$ (1.74)
Net loss per share attributable to common stockholders, diluted	$ (0.87)	$ (0.53)	$ (2.38)	$ (1.74)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic	38,054,583	37,817,724	37,993,002	37,693,830
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted	38,054,583	37,817,724	37,993,002	37,693,830